Clinical trials: Inhalation
Asthma, Healthy Volunteers
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729 for up to 28 Days
RV1729 is a new medicine being developed for the potential treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD).
- Trial name
- NCT02140320
- Testing
- RV1729 single dose, RV1729 14 day repeat dose, RV1729 28 day repeat dose
- Where
- 2 sites in United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Respivert Ltd
Asthma
Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)
Bronchial asthma is among the world's most prevalent diseases. Roflumilast is a novel, orally active, selective enzyme inhibitor (phosphodiesterase 4 inhibitor), which has shown effectiveness in the treatment of asthma.
- Trial name
- NCT00163527
- Testing
- Roflumilast
- Where
- 24 sites in United States, Austria and 22 more
- Volunteers
- 2,054 people
- Sponsor
- AstraZeneca
Lung Cancer
A Study to Diagnose Lung Cancer by Sputum Cytology (01-312)
The primary objective of this study is to determine if more diagnoses of lung cancer are obtained from the cytological evaluation of sputum expectorated following a single inhaled dose of UTP compared to sputum expectorated…
- Trial name
- NCT00210080
- Testing
- Uridine 5'-Triphosphate (UTP) Solution for Inhalation
- Volunteers
- 700 people
- Sponsor
- Merck Sharp & Dohme LLC
Cystic Fibrosis (CF)
Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult Volunteers
This study will be performed to assess the safety, tolerability and PK of escalating inhaled AIR-DNase doses administered as a single dose followed by multiple doses for 5 consecutive days in healthy subjects.
- Trial name
- NCT02605590
- Testing
- AIR DNase
- Where
- Israel
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Protalix
Asthma
A Study to Evaluate the Effects of Indacaterol Maleate (QAB149) as a New Formulation in the EPIC Test Fixture
This study will assess the pharmacodynamics, safety, tolerability and pharmacokinetics of indacaterol maleate (QAB149), administered via the EPIC test fixture.
- Trial name
- NCT01845623
- Testing
- QAB149 75 mg Concept 1, QAB149 75 mg Epic Test Fixture
- Sponsor
- Novartis Pharmaceuticals
Asthma
Effects Of Repeat Inhaled Doses Of GW597901X On Patient Safety And Lung Function In Asthmatic Subjects
This study is designed to look at the safety aspects and effects of repeat inhaled doses of GW597901X in asthmatics to develop this drug for its use in asthma and Chronic Obstructive Pulmonary Disease(COPD).
- Trial name
- NCT00354042
- Testing
- GW597901X
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Asthma
A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist
The purpose of this study is to continue to characterize the safety profile of benralizumab administration and monitor the pharmacodynamic activity of the drug in those asthma patients who remain on treatment for at least 16…
- Trial name
- MELTEMI (NCT02808819)
- Testing
- Benralizumab
- Where
- 178 sites in United States, Argentina and 13 more
- Volunteers
- 447 people
- Sponsor
- AstraZeneca
Haemorrhage
A Non-investigational Product (IP) Study to Investigate Lung Function in Women in the Third Stage of Labour
The purpose of this study is to record and compare the inhalation profiles of non pregnant women and those who are in the third stage of labour.
- Trial name
- NCT02106000
- Testing
- Inhalation profile recorder
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.
For asthmatic subjects, a combination of inhaled corticosteroid (FF) and long-acting beta2 receptor agonist (VI) is recommended for use (once daily) and fraction of exhaled nitric oxide (FeNO) is a non-invasive airway…
- Trial name
- NCT02712047
- Testing
- Fluticasone furoate (FF) (100 mcg), Vilanterol (VI) (25 mcg)
- Where
- New Zealand
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Asthma
BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging
This study will assess the effects of benralizumab on airway dynamics in severe eosinophilic asthma in terms of quantitative computed tomography (CT)-derived measurements of pulmonary structure and function using the Functional…
- Trial name
- BURAN (NCT05552508)
- Testing
- Benralizumab
- Where
- 25 sites in United States, Australia and 5 more
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Pulmonary Arterial Hypertension
Efficacy of Ventavis Used in Real-life Setting.
This is a registry of patients diagnosed with pulmonary arterial hypertension, scheduled for treatment with Ventavis. Typical clinical measures and quality of life will be prospectively followed in 12 months period.
- Trial name
- SPHERA (NCT01355380)
- Testing
- Inhaled iloprost (Ventavis, BAYQ6256)
- Where
- Poland
- Volunteers
- 55 people
- Sponsor
- Bayer
Respiratory Syncytial Virus Infection
A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171
The primary objective of the study is to investigate the safety and tolerability of ALX-0171. The secondary objectives are to evaluate the clinical effect of ALX-0171 and to explore the pharmacodynamics (PD) and the systemic…
- Trial name
- NCT02309320
- Testing
- ALX-0171
- Where
- 59 sites in Australia, Belgium and 12 more
- Volunteers
- 53 people
- Sponsor
- Ablynx, a Sanofi company
Asthma
A Blinded, Dose Ascending Study to Assess the Pharmacokinetics, Safety and Tollerability of Repeat Inhaled Doses of Nebulised GW870086X in Healthy Adult Male Volunteers.
This study is a randomised, double-blind, placebo-controlled, dose ascending, 3-way crossover study in healthy adult male volunteers.
- Trial name
- SIG (NCT01160003)
- Testing
- GW870086X
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cystic Fibrosis
A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis
Ascending dose, 7-day, open label safety trial of SPX-101 Inhalation Solution in adult subjects with cystic fibrosis.
- Trial name
- NCT03056989
- Testing
- SPX-101
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Spyryx Biosciences, Inc.
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
The purpose of this 12 week study is to evaluate the effects of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticasone propionate (250/50mcg) twice-daily and umeclidinium bromide (125mcg) once-daily to…
- Trial name
- NCT01772147
- Testing
- Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg
- Where
- 55 sites in United States, Chile and 3 more
- Volunteers
- 608 people
- Sponsor
- GlaxoSmithKline
Healthy Volunteers, Safety
Safety of Ascending Single and Multiple Doses of Nebulised SoftOx Inhalation Solution in Healthy Subjects
Background: This first-in-human study will investigate the safety and tolerability of single and multiple doses of nebulised SoftOx Inhalation Solution (SIS) delivered via a jet nebuliser to healthy subjects.
- Trial name
- NCT05188638
- Testing
- SoftOx Inhaled Solution (SIS)
- Where
- Denmark
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- SoftOx Solutions AS
Pulmonary Disease, Chronic Obstructive
A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.
GW642444 and GSK233705 are in development for treatment of Chronic Obstructive Pulmonary Disease. Development of these two inhaled drugs as a combination therapy would have potential for improved patient benefit as they both work…
- Trial name
- NCT00671216
- Testing
- GSK233705, GW642444, GSK233705 and GW642444
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cystic Fibrosis
Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.
It is hypothesized that the inhalation of sodium pyruvate will reduce lung damage in patients with Cystic Fibrosis (CF) by its ability to reduce levels of toxic reactive oxygen and nitrogen compounds associated with the chronic…
- Trial name
- NCT00308243
- Testing
- Sodium Pyruvate in 0.9% Sodium Chloride Solution
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Emphycorp
Healthy Volunteers
An Exploratory PET-study of Deposition, Disposition and Brain Uptake of [11C]Nicotine After Inhalation of 2 Nicotine Formulations Via the myBluTM E-cigarette in Smokers
This is a single-center, exploratory positron emission tomography (PET) study of deposition, disposition and brain uptake [11C]nicotine when given to smokers as two different formulations via mybluTM e-cigarette system.
- Trial name
- NCT04780815
- Testing
- myBluTM Formulation 1, myBluTM Formulation 2
- Where
- Sweden
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Imperial Brands PLC
Cannabis Use, Cachexia; Cancer
Safety and Efficacy of Inhaled Synthetic THC/CBD for Improving Physical Functioning and for Modulating Cachexia Progression in Patients With Advanced Cancer and Associated Cachexia
A large number of patients with advanced cancer also suffer from cachexia. Cachexia is a syndrome characterized by loss of skeletal muscle mass (with/or without loss of fat mass) that cannot be reversed by nutritional support and…
- Conditions
- Cannabis Use, Cachexia; Cancer, Advanced Cancer
- Trial name
- SERENITY (NCT04001010)
- Testing
- PPP011
- Where
- Canada
- Volunteers
- 334 people
- Sponsor
- Tetra Bio-Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.